Skip to content

Effect of Amniotic Membrane Dressing in Donor Graft Site

Comparison of Outcomes of Amniotic Membrane Dressing with Conventional Dressing in Donor Graft Site of Patients with Donor Site of Patients Admitted in Mousavi Hospital, Zanjan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200615047782N1
Enrollment
36
Registered
2020-07-09
Start date
2020-07-22
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients suffered thermal burns in need skin graft. Exposure to unspecified smoke, fire and flames

Interventions

Intervention 1: Intervention group: the intervention sites with a thickness of 0.4 to 0.6 mm are given using an electric dermatome with the same level of oxidation
Bleeding is controlled using epinephrine 1 in 50,000 with sterile gauze. One of the donor sites is randomly covered with an amniotic membrane. Amniotic membrane is taken from sero negative mothers who
Bleeding is controlled using epinephrine 1 in 50,000 with sterile gauze. One of the donor sites is accidentally covered with ordinary dressing, ie Vaseline gas (control group).In the control group, th

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
7 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with second- or third-degree burns or patients who need a semi-thick skin graft for any other reason and have a donor site Donor location in the limbs No injuries other than burns General physical and mental health Age between 7 years and 60 years Other conditions, such as trauma, are less than 40 percent of the wound and are on the limb and need to be removed

Exclusion criteria

Exclusion criteria: Patients with blood-borne viral infections including hepatitis B and C and HIV Dissatisfaction of patients to enter the study Lack of follow-up ability Presence of any cerebrovascular, cardiovascular, endocrine, liver and kidney diseases; Pregnancy History of alcohol and drug abuse Concomitant use of antibiotics (orally and topically) Concomitant use of steroids or immunosuppressive drugs Infected patients at the donor site

Design outcomes

Primary

MeasureTime frame
Scar percentage. Timepoint: The amount of scar on the fifth, fourteenth, and finally thirty-sixth days is evaluated as outpatient in the clinic by the relevant professor and its amount is recorded with a qualitative scale of 4 items: excellent, good, average, weak. Method of measurement: A measure of the body's scar level that is measured objectively.;Healing rate. Timepoint: The time required for wound healing on the fifth, fourteenth, and finally 30th days of the clinic is evaluated on an outpatient basis by the relevant professor and its amount is recorded with a qualitative scale of 4 items: excellent, good, average, weak. Method of measurement: Healed: the wound area where the medicine wasapplied is completely healed ObviouslyEffective:70 % of the wound is healed Effective: over 30 % of the wound is healed Ineffective: the effective standard is not met.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Hosein Moghimi

Zanjan University of Medical Sciences

Mohammadhosein_moghimi@yahoo.com+98 24 3310 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026